Recent BBIO News
- BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) • GlobeNewswire Inc. • 06/18/2024 11:30:00 AM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/10/2024 11:30:00 AM
- BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference • GlobeNewswire Inc. • 06/06/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 10:01:23 AM
- BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024 • GlobeNewswire Inc. • 06/03/2024 08:01:00 PM
- Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) • GlobeNewswire Inc. • 05/29/2024 08:01:00 PM
- BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting • GlobeNewswire Inc. • 05/24/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 08:09:25 PM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/15/2024 11:30:00 AM
- BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024 • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensiti • GlobeNewswire Inc. • 05/13/2024 11:30:00 AM
- BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline • GlobeNewswire Inc. • 05/02/2024 11:00:00 AM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/10/2024 11:30:00 AM
- BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) • GlobeNewswire Inc. • 04/07/2024 05:15:00 PM
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/20/2024 11:30:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/06/2024 10:15:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 10:13:04 PM
- BridgeBio Pharma Announces Pricing of Public Offering of Common Stock • GlobeNewswire Inc. • 03/06/2024 04:53:56 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/04/2024 10:25:14 PM
- BridgeBio Pharma Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/04/2024 09:17:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:00:28 PM
- BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM • GlobeNewswire Inc. • 03/04/2024 07:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 09:27:58 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM